Journal article
Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience
Hamish W Scott, Mark R Dowling, Daniel Garcia, Samantha van der Linde, Nicole O'Leary, Brydon Panozzo, Adrian Minson, James A Kuzich, Aaron Jun Ning Wong, Michael S Hofman, Monique Youl, Belinda Campbell, Michael Patrick Macmanus, Philip A Thompson, Mary Ann Anderson, John F Seymour, Michael J Dickinson, Simon J Harrison
Blood | American Society of Hematology | Published : 2024
Abstract
Aim: Autologous anti-CD19 CAR T-cell therapy is an established standard-of-care (SOC) for relapsed/refractory (R/R) LBCL, but successful delivery requires disease control through the manufacturing period. The effects of bridging radiotherapy (RT) on outcome are unclear and impacted by disease factors such as bulk and distribution. We sought to compare outcomes of patients receiving RT-alone versus systemic-based bridging therapies (BT) delivered after apheresis and prior to axi-cel infusion. Method: Data were collected retrospectively for all patients with R/R LBCL treated with SOC axi-cel between 2020-2024 with ≥3 months of follow-up pos..
View full abstract